Alector, Inc.ALECEarnings & Financial Report
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for neurodegenerative diseases. Its product pipeline targets unmet medical needs including Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease, and it collaborates with global pharmaceutical partners to advance candidate therapies through clinical trials.
ALEC Q4 FY2025 Key Financial Metrics
Revenue
$6.2M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-88.5%
Alector, Inc. Q4 FY2025 Financial Summary
Alector, Inc. reported revenue of $6.2M (down 88.5% YoY) for Q4 FY2025, with a net profit of N/A (down 1696.9% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $6.2M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Alector, Inc. Annual Revenue by Year
Alector, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $21.0M).
Alector, Inc. Quarterly Revenue & Net Profit History
Alector, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $6.2M | -88.5% | N/A | N/A |
| Q3 FY2025 | $3.3M | -78.8% | $-34.7M | -1063.4% |
| Q2 FY2025 | $7.9M | -47.8% | $-30.5M | -387.7% |
| Q1 FY2025 | $3.7M | -76.9% | $-40.5M | -1101.6% |
| Q4 FY2024 | $54.2M | +257.1% | $-2.1M | -3.8% |
| Q3 FY2024 | $15.3M | +68.4% | $-42.2M | -275.2% |
| Q2 FY2024 | $15.1M | -73.2% | $-38.7M | -256.4% |
| Q1 FY2024 | $15.9M | -4.0% | $-36.1M | -227.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.9M | $15.1M | $15.3M | $54.2M | $3.7M | $7.9M | $3.3M | $6.2M |
| YoY Growth | -4.0% | -73.2% | 68.4% | 257.1% | -76.9% | -47.8% | -78.8% | -88.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $635.5M | $570.7M | $516.0M | $468.3M | $408.3M | $356.4M | $335.3M | $293.2M |
| Liabilities | $456.6M | $420.2M | $397.1M | $341.5M | $313.7M | $285.2M | $277.6M | $262.6M |
| Equity | $178.9M | $150.6M | $118.9M | $126.8M | $94.6M | $71.2M | $57.7M | $30.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-61.3M | $-62.8M | $-50.7M | $-55.0M | $-60.8M | $-49.0M | $-32.5M | $-184.0M |